🇺🇸 ESTROGEN in United States

FDA authorised ESTROGEN on 30 July 1999 · 3,533 US adverse-event reports

Marketing authorisations

FDA — authorised 30 July 1999

  • Application: ANDA075357
  • Marketing authorisation holder: L PERRIGO CO
  • Status: approved

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Nausea — 488 reports (13.81%)
  2. Drug Ineffective — 458 reports (12.96%)
  3. Fatigue — 451 reports (12.77%)
  4. Headache — 425 reports (12.03%)
  5. Pain — 339 reports (9.6%)
  6. Dizziness — 289 reports (8.18%)
  7. Breast Cancer — 287 reports (8.12%)
  8. Diarrhoea — 272 reports (7.7%)
  9. Anxiety — 267 reports (7.56%)
  10. Arthralgia — 257 reports (7.27%)

Source database →

ESTROGEN in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is ESTROGEN approved in United States?

Yes. FDA authorised it on 30 July 1999; FDA has authorised it.

Who is the marketing authorisation holder for ESTROGEN in United States?

L PERRIGO CO holds the US marketing authorisation.